Published in Gut on December 01, 1977
Initiation of replication of the human hepatitis delta virus genome from cloned DNA: role of delta antigen. J Virol (1989) 5.48
Structure and replication of the genome of the hepatitis delta virus. Proc Natl Acad Sci U S A (1986) 5.23
delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A (1980) 5.12
Molecular cloning of hepatitis delta virus RNA from an infected woodchuck liver: sequence, structure, and applications. J Virol (1988) 4.96
A specific base transition occurs on replicating hepatitis delta virus RNA. J Virol (1990) 4.05
The large form of hepatitis delta antigen is crucial for assembly of hepatitis delta virus. Proc Natl Acad Sci U S A (1991) 3.52
Hybrid DNA virus in Chinese patients with seronegative hepatitis discovered by deep sequencing. Proc Natl Acad Sci U S A (2013) 3.35
Human hepatitis delta antigen is a nuclear phosphoprotein with RNA-binding activity. J Virol (1988) 3.11
A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta. J Virol (1988) 2.99
Transmission of the hepatitis B virus-associated delta agent to the eastern woodchuck. Proc Natl Acad Sci U S A (1984) 2.87
Delta hepatitis agent: structural and antigenic properties of the delta-associated particle. Infect Immun (1984) 2.81
Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev (1999) 2.55
Replication of human hepatitis delta virus in primary cultures of woodchuck hepatocytes. J Virol (1987) 2.36
Assembly of hepatitis delta virus particles. J Virol (1992) 2.36
Characterization of hepatitis delta antigen: specific binding to hepatitis delta virus RNA. J Virol (1990) 2.17
Hepatitis delta virus genome replication: a polyadenylated mRNA for delta antigen. J Virol (1990) 2.03
Kinetics of delta antigen and delta antibody in acute delta hepatitis: evaluation with different enzyme immunoassays. J Clin Microbiol (1988) 1.87
Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol (2004) 1.76
Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion. J Virol (1993) 1.65
Characterization of nuclear targeting signal of hepatitis delta antigen: nuclear transport as a protein complex. J Virol (1992) 1.63
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis (2015) 1.59
Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis (2010) 1.58
Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol (2010) 1.56
Enzyme-linked immunosorbent assay for detection of antibody to the hepatitis B surface antigen-associated delta antigen. J Clin Microbiol (1981) 1.47
Heterogeneity and evolution rates of delta virus RNA sequences. J Virol (1990) 1.45
Significance of delta agent infection in chronic hepatitis B virus infection: a study in British carriers. Gut (1983) 1.40
Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol (2014) 1.36
Parameters of human hepatitis delta virus genome replication: the quantity, quality, and intracellular distribution of viral proteins and RNA. J Virol (2002) 1.29
Clinical aspects of delta infection. Br Med J (Clin Res Ed) (1983) 1.25
Microsomal autoantibodies in chronic infection with the HBsAg associated delta (delta) agent. Clin Exp Immunol (1983) 1.13
A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J Virol (2002) 1.13
HDV-like self-cleaving ribozymes. RNA Biol (2011) 1.12
Hepatitis delta antigen mediates the nuclear import of hepatitis delta virus RNA. J Virol (1998) 1.12
Genomic but not antigenomic hepatitis delta virus RNA is preferentially exported from the nucleus immediately after synthesis and processing. J Virol (2002) 1.10
Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol (2003) 1.08
Nuclear localization signals, but not putative leucine zipper motifs, are essential for nuclear transport of hepatitis delta antigen. J Virol (1992) 1.07
Self-cleavage of a 71 nucleotide-long ribozyme derived from hepatitis delta virus genomic RNA. Nucleic Acids Res (1991) 1.01
Large hepatitis delta antigen is not a suppressor of hepatitis delta virus RNA synthesis once RNA replication is established. J Virol (2002) 0.99
Epidemiological, clinical and histological characteristics of HBV/HDV co-infection: a retrospective cross-sectional study in Guangdong, China. PLoS One (2014) 0.98
Delta agent infection in acute hepatitis and chronic HBsAg carriers with and without liver disease. Gut (1984) 0.95
Delta hepatitis: molecular biology and clinical and epidemiological features. Clin Microbiol Rev (1993) 0.94
Large hepatitis delta antigen is a novel clathrin adaptor-like protein. J Virol (2007) 0.93
Purinergic receptor functionality is necessary for infection of human hepatocytes by hepatitis delta virus and hepatitis B virus. PLoS One (2010) 0.91
Origin of hepatitis delta virus. Future Microbiol (2010) 0.91
Roles of carboxyl-terminal and farnesylated residues in the functions of the large hepatitis delta antigen. J Virol (2005) 0.89
Unthought-of problems regarding hepatitis D virus infection. Hepat Mon (2010) 0.89
Casein kinase II and protein kinase C modulate hepatitis delta virus RNA replication but not empty viral particle assembly. J Virol (1996) 0.88
Experimental transmission of the delta virus to a hepatitis B chronic carrier chimpanzee with the development of persistent delta carriage. Am J Pathol (1986) 0.88
3-D models of the antigenomic ribozyme of the hepatitis delta agent with eight new contacts suggested by sequence analysis of 188 cDNA clones. Nucleic Acids Res (1995) 0.88
Transfer of Viral Communities between Human Individuals during Fecal Microbiota Transplantation. MBio (2016) 0.88
Hepatitis C-Z: recent advances. Arch Dis Child (2002) 0.88
Evolution and diversity of the human hepatitis d virus genome. Adv Bioinformatics (2010) 0.87
Phosphorylation of the hepatitis delta virus antigens. J Virol (1997) 0.87
Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Curr Gastroenterol Rep (2014) 0.86
Activation of heterologous gene expression by the large isoform of hepatitis delta antigen. J Virol (1998) 0.86
Transcription factor YY1 and its associated acetyltransferases CBP and p300 interact with hepatitis delta antigens and modulate hepatitis delta virus RNA replication. J Virol (2008) 0.85
Prevalence of hepatitis d in the eastern mediterranean region: systematic review and meta analysis. Hepat Mon (2013) 0.84
Hepatitis delta virus RNA replication. Viruses (2009) 0.84
Clathrin-mediated post-Golgi membrane trafficking in the morphogenesis of hepatitis delta virus. J Virol (2009) 0.84
Alpha interferon and ribavirin combination therapy of chronic hepatitis D. Antimicrob Agents Chemother (2005) 0.83
Current prevalence of hepatitis delta virus (HDV) infection and the range of HDV genotypes in Lebanon. Epidemiol Infect (2006) 0.83
Pathologic and ultrastructural changes of acute and chronic delta hepatitis in an experimentally infected chimpanzee. Am J Pathol (1986) 0.83
An RNA tertiary structure of the hepatitis delta agent contains UV-sensitive bases U-712 and U-865 and can form in a bimolecular complex. Nucleic Acids Res (1995) 0.83
Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Nat Rev Gastroenterol Hepatol (2016) 0.82
The delta agent comes of age. Gut (1985) 0.82
Mortality and morbidity among military personnel and civilians during the 1930s and World War II from transmission of hepatitis during yellow fever vaccination: systematic review. Am J Public Health (2013) 0.81
Acute delta hepatitis without circulating HBsAg. Gut (1985) 0.81
Hepatocellular carcinoma in hepatitis D: does it differ from hepatitis B monoinfection? Saudi J Gastroenterol (2012) 0.81
Viral hepatitis: past and future of HBV and HDV. Cold Spring Harb Perspect Med (2015) 0.80
Efficient expression of histidine-tagged large hepatitis delta antigen in baculovirus-transduced baby hamster kidney cells. World J Gastroenterol (2006) 0.79
Tm studies of a tertiary structure from the human hepatitis delta agent which functions in vitro as a ribozyme control element. Nucleic Acids Res (1995) 0.79
Pegylated Interferon α Therapy in Chronic Delta Hepatitis: A One-Center Experience. Hepat Mon (2015) 0.79
Interferon impedes an early step of hepatitis delta virus infection. PLoS One (2011) 0.78
Hepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected Hepatocyte. J Clin Transl Hepatol (2015) 0.78
Development of an enzyme immunoassay using recombinant expressed antigen to detect hepatitis delta virus antibodies. J Clin Microbiol (1989) 0.78
Hepatitis delta virus: Making the point from virus isolation up to 2014. World J Hepatol (2015) 0.78
Prevalence of hepatitis d virus infection among patients with chronic hepatitis B attending birjand hepatitis clinic (East of iran) in 2012. Hepat Mon (2013) 0.78
Host RNA circles and the origin of hepatitis delta virus. World J Gastroenterol (2014) 0.77
Identification and characterization of novel small-molecule inhibitors against hepatitis delta virus replication by using docking strategies. Hepat Mon (2011) 0.77
Hepatitis delta infections. Br Med J (Clin Res Ed) (1985) 0.76
Animal models of chronic hepatitis delta virus infection host-virus immunologic interactions. Pathogens (2015) 0.76
Improving hepatitis B vaccine efficacy in end-stage renal diseases patients and role of adjuvants. ISRN Gastroenterol (2012) 0.76
Hepatitis delta virus in homosexual men in Sydney. Genitourin Med (1989) 0.76
Identification of a binding site for ASF/SF2 on an RNA fragment derived from the hepatitis delta virus genome. PLoS One (2013) 0.76
Experimental models of hepatitis B and C - new insights and progress. Nat Rev Gastroenterol Hepatol (2016) 0.76
Therapy of Delta Hepatitis. Cold Spring Harb Perspect Med (2015) 0.76
Interferon alpha-2b therapy in chronic hepatitis delta. Hepat Mon (2014) 0.75
Hepatitis delta virus: A fascinating and neglected pathogen. World J Virol (2015) 0.75
Hepatology. Postgrad Med J (1991) 0.75
Hepatitis viruses: characterization and diagnostic techniques. Yale J Biol Med (1980) 0.75
Prevalence and genotype distribution of hepatitis delta virus among chronic hepatitis B carriers in Central Vietnam. PLoS One (2017) 0.75
Anti-Transcription Factor RNA Aptamers as Potential Therapeutics. Nucleic Acid Ther (2015) 0.75
Clinicopathological study of fulminant hepatitis: coinfection with hepatitis B virus and delta agent. CMAJ (1986) 0.75
Estimation of the secondary attack rate for delta hepatitis coinfection among injection drug users. Can J Infect Dis (1993) 0.75
Is Hepatitis Delta infections important in Brazil? BMC Infect Dis (2016) 0.75
Delta hepatitis in Denver. West J Med (1988) 0.75
PCR-Based Molecular Diagnosis of Hepatitis Virus (HBV and HDV) in HCV Infected Patients and Their Biochemical Study. J Pathog (2016) 0.75
Towards the elimination and eradication of hepatitis B. J Virus Erad (2015) 0.75
Clinical and histological features of delta infection in chronic hepatitis B virus carriers. J Clin Pathol (1985) 0.75
Serological responses to HBV infection. Gut (1986) 0.75
New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants. J Immunol (1972) 6.33
Antibody to hepatitis-B-virus core in man. Lancet (1973) 4.24
Pattern of core and surface expression in liver tissue reflects state of specific immune response in hepatitis B. Lab Invest (1975) 2.97
Differential distribution of hepatitis B surface antigen and hepatitis B core antigen in the liver of hepatitis B patients. Gastroenterology (1976) 2.17
Differential distribution of Australia-antigen-associated particles in patients with liver diseases and normal carriers. N Engl J Med (1973) 1.86
The virus of hepatitis, type B (first of two parts). N Engl J Med (1976) 1.64
Immune complexes in hepatocytic nuclei of HB ag-positive chronic hepatitis. N Engl J Med (1976) 1.35
A study on antibodies produced with liver tissue containing Australia antigen and virus-like particles. Lab Invest (1973) 1.29
Intrahepatic localization of the surface (HBsAg) and core (HBcAg) antigenic determinants associated with hepatitis B virus in biopsy samples from patients with liver disease. Ric Clin Lab (1976) 1.27
Complement fixing hepatitis B core antigen immune complexes in the liver of patients with HBs antigen positive chronic disease. Gut (1976) 1.23
Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet (1990) 8.56
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med (1998) 6.23
delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A (1980) 5.12
Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A (1992) 4.47
Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology (1991) 4.47
Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis (1980) 4.28
A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology (1994) 4.01
Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science (1999) 3.85
The delta agent. Hepatology (1983) 3.72
Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope. J Virol (1986) 3.63
The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol (1977) 3.07
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology (2001) 3.02
Types of 'reticulin' antibodies detected in human sera by immunofluorescence. J Clin Pathol (1973) 2.98
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 2.97
Transmission of the hepatitis B virus-associated delta agent to the eastern woodchuck. Proc Natl Acad Sci U S A (1984) 2.87
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat (2007) 2.87
Delta hepatitis agent: structural and antigenic properties of the delta-associated particle. Infect Immun (1984) 2.81
Detection of hepatitis B virus DNA in liver and serum: a direct appraisal of the chronic carrier state. Lancet (1981) 2.80
Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia (2005) 2.67
Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours. Nature (1990) 2.61
Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol (1973) 2.59
Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet (2000) 2.58
The hepatitis B virus-associated delta antigen: isolation from liver, development of solid-phase radioimmunoassays for delta antigen and anti-delta and partial characterization of delta antigen. J Immunol (1980) 2.57
T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology (1993) 2.39
Hepatitis B virus DNA in the sera of HBsAg carriers: a marker of active hepatitis B virus replication in the liver. Hepatology (1982) 2.38
Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology (1993) 2.32
Influence of delta infection on severity of hepatitis B. Lancet (1982) 2.31
Incidence and significance of antibodies to delta antigen in hepatitis B virus infection. Lancet (1979) 2.29
Waterborne outbreak of intestinal microsporidiosis in persons with and without human immunodeficiency virus infection. J Infect Dis (1999) 2.20
Epidemiology of HBV-associated delta agent: geographical distribution of anti-delta and prevalence in polytransfused HBsAg carriers. Lancet (1980) 2.17
Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med (1983) 2.16
Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol (2007) 2.12
A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med (1995) 2.06
Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A (1991) 2.05
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat (2011) 2.00
Efficacy of amoxycillin plus clavulanic acid-based triple therapy for Helicobacter pylori eradication: a retrospective study. Panminerva Med (2010) 1.99
Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med (1993) 1.90
Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat (2001) 1.89
Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors. J Biol Chem (1995) 1.88
Symptomatic relapse of neurologic syphilis after benzathine penicillin G therapy for primary or secondary syphilis in HIV-infected patients. Clin Infect Dis (2006) 1.77
Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology (1986) 1.75
Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology (1993) 1.75
Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology (1997) 1.74
Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology (1998) 1.69
Acquired protein S deficiency: correlation with advanced disease in HIV-1-infected patients. J Acquir Immune Defic Syndr (1992) 1.67
Serological pattern "anti-HBc alone": report on a workshop. J Med Virol (2000) 1.65
Hepatic disorders associated with liver-kidney microsomal antibodies. Br Med J (1974) 1.64
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat (2005) 1.64
Plasma membrane hydroxyethyl radical adducts cause antibody-dependent cytotoxicity in rat hepatocytes exposed to alcohol. Gastroenterology (1997) 1.63
Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer (2008) 1.59
Detection of intrahepatic replication of hepatitis C virus RNA by in situ hybridization and comparison with histopathology. Proc Natl Acad Sci U S A (1992) 1.56
Chronic Helicobacter pylori infection and migraine: a case-control study. Headache (2001) 1.54
Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial. Hepatology (1998) 1.53
Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol (1999) 1.52
Serological response to the hepatitis delta virus in hepatitis D. Lancet (1987) 1.50
Helicobacter pylori seroprevalence in cirrhotic patients with hepatitis B virus infection. Neth J Med (2000) 1.50
Characterization of the microsomal antigen related to a subclass of active chronic hepatitis. Immunology (1974) 1.50
Randomized controlled trial of adenine arabinoside 5'-monophosphate in chronic active hepatitis B: comparison of the efficacy in heterosexual and homosexual patients. Hepatology (1989) 1.50
Multicentre study of prevalence of HBV-associated delta infection and liver disease in drug-addicts. Lancet (1982) 1.50
Systemic nitric oxide production and renal function in nonazotemic human cirrhosis: a reappraisal. Am J Gastroenterol (2002) 1.49
Infection with the delta agent in chronic HBsAg carriers. Gastroenterology (1981) 1.48
Incidence of hepatitis delta virus infection in acute HBsAg-negative hepatitis. J Infect Dis (1989) 1.48
Epidemiologic patterns of infection with the hepatitis B virus-associated delta agent in Italy. Am J Epidemiol (1983) 1.47
The delta agent: HBsAg particles with delta antigen and RNA in the serum of an HBV carrier. Hepatology (1981) 1.47
Attributable risk for symptomatic liver cirrhosis in Italy. Collaborative Groups for the Study of Liver Diseases in Italy. J Hepatol (1998) 1.47
IgM antibody against measles virus in patients with inflammatory bowel disease: a marker of virus-related disease? Eur J Gastroenterol Hepatol (1997) 1.47
Enzyme-linked immunosorbent assay for detection of antibody to the hepatitis B surface antigen-associated delta antigen. J Clin Microbiol (1981) 1.47
The HBV HBX gene expressed in E. coli is recognised by sera from hepatitis patients. EMBO J (1985) 1.45
Measles IgM immunoreactivity in patients with inflammatory bowel disease. Ital J Gastroenterol Hepatol (1998) 1.44
Randomised, double-blind, placebo-controlled trial of ditiocarb sodium ('Imuthiol') in human immunodeficiency virus infection. Lancet (1988) 1.43
A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. Hepatology (1989) 1.43
Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. J Hepatol (2001) 1.43
Monoethyl glycine xylidide (MEGX) test evaluation in primary biliary cirrhosis: comparison with Mayo score. Eur J Gastroenterol Hepatol (1997) 1.42
Molecular analysis of V(H)I+ B lymphocytes in hepatitis C patients. Dig Liver Dis (2003) 1.40
Efficacy of azythromicin-based triple therapy for Helicobacter pylori infection: a retrospective study. Panminerva Med (2008) 1.39
Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis (2002) 1.39
Striking aminotransferase rise after chlorhexidine self-poisoning. Lancet (1982) 1.38
Radioimmunoassay detection of IgM antibodies to the HBV-associated delta (delta) antigen:" clinical significance in delta infection. J Med Virol (1982) 1.38
Horse antilymphocytic globulin in hepatitis B exacerbation after bone marrow transplantation adoptive immunity transfer. Bone Marrow Transplant (2004) 1.37